Market Overview

UPDATE: Piper Jaffray Raises Price Target on Trius Therapeutics to $15


According to Piper Jaffray, Trius Therapeutics (NASDAQ: TSRX) price target is raised to $15.

Piper Jaffray said that following positive results from the 1st pivotal tedizolid trial, Trius is a Top Pick for 2012. “We reiterate our Overweight rating and are increasing our price target to $15 from $12.”

Trius Therapeutics closed on Friday at $7.15.

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (TSRX)

Get Benzinga's Newsletters